摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl (R)-2-(2-naphthamido)-5-(3-fluorophenyl)pent-4-ynoate | 1227832-86-1

中文名称
——
中文别名
——
英文名称
ethyl (R)-2-(2-naphthamido)-5-(3-fluorophenyl)pent-4-ynoate
英文别名
——
ethyl (R)-2-(2-naphthamido)-5-(3-fluorophenyl)pent-4-ynoate化学式
CAS
1227832-86-1
化学式
C24H20FNO3
mdl
——
分子量
389.426
InChiKey
UWBUVYRRLPQFMX-JOCHJYFZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.08
  • 重原子数:
    29.0
  • 可旋转键数:
    5.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    55.4
  • 氢给体数:
    1.0
  • 氢受体数:
    3.0

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    ethyl (R)-2-(2-naphthamido)-5-(3-fluorophenyl)pent-4-ynoate 在 palladium 10% on activated carbon 、 氢气 作用下, 以 乙酸乙酯 为溶剂, 生成
    参考文献:
    名称:
    Structure-based design of novel human Pin1 inhibitors (II)
    摘要:
    Following the discovery of a novel series of phosphate-containing small molecular Pin1 inhibitors, the drug design strategy shifted to replacement of the phosphate group with an isostere with potential better pharmaceutical properties. The initial loss in potency of carboxylate analogs was likely due to weaker charge-charge interactions in the putative phosphate binding pocket and was subsequently recovered by structure-based optimization of ligand-protein interactions in the proline binding site, leading to the discovery of a sub-micromolar non-phosphate small molecular Pin1 inhibitor. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.02.033
  • 作为产物:
    描述:
    ethyl (R)-2-(2-naphthamido)pent-4-ynoate间氟碘苯 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide二异丙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 0.5h, 以75%的产率得到ethyl (R)-2-(2-naphthamido)-5-(3-fluorophenyl)pent-4-ynoate
    参考文献:
    名称:
    Structure-based design of novel human Pin1 inhibitors (II)
    摘要:
    Following the discovery of a novel series of phosphate-containing small molecular Pin1 inhibitors, the drug design strategy shifted to replacement of the phosphate group with an isostere with potential better pharmaceutical properties. The initial loss in potency of carboxylate analogs was likely due to weaker charge-charge interactions in the putative phosphate binding pocket and was subsequently recovered by structure-based optimization of ligand-protein interactions in the proline binding site, leading to the discovery of a sub-micromolar non-phosphate small molecular Pin1 inhibitor. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2010.02.033
点击查看最新优质反应信息